TY - JOUR
T1 - The Association of Prenatal Vitamin D Sufficiency With Aeroallergen Sensitization and Allergic Rhinitis in Early Childhood
AU - Chen, Yih Chieh S.
AU - Mirzakhani, Hooman
AU - Lu, Mengdi
AU - Zeiger, Robert S.
AU - O'Connor, George T.
AU - Sandel, Megan T.
AU - Bacharier, Leonard B.
AU - Beigelman, Avraham
AU - Carey, Vincent J.
AU - Harshfield, Benjamin J.
AU - Laranjo, Nancy
AU - Litonjua, Augusto A.
AU - Weiss, Scott T.
AU - Lee-Sarwar, Kathleen A.
N1 - Funding Information:
The National Health, Lung and Blood Institute ( NHLBI ) awarded Grants R01 HL091528 and UH3 OD023268 to S. T. Weiss and A. A. Litonjua. Y-C. S. Chen is supported by Grants T-32 HL007427 and T-32 AI007306 from the NHLBI . K. A. Lee-Sarwar is supported by Grant K08 from the NHLBI ( K08HL148178 ), and H. Mirzakhani is supported by Grant K01 from the NHLBI ( 1K01HL146977-01A1 ).
Funding Information:
Conflicts of interest: A. A. Litonjua has received author royalties from UpToDate, Inc. S. T. Weiss has received royalties from UpToDate, Inc. L. B. Bacharier participates on the Data Safety Monitoring Board of DBV Technologies. A. Beigelman has received research support from the NHLBI and holds stock from DBV Technologies . R. S. Zeiger is a consultant for AstraZeneca, DBV Technologies, Genentech, Inc, GlaxoSmithKline, Novartis, and Regeneron, and has received research support from Aerocrine, AstraZeneca, Genentech, Inc, GlaxoSmithKline, MedImmune, Merck, the NHLBI, Quest Diagnostics, and TEVA Pharmaceuticals. G. T. O'Connor is a coinvestigator on a grant from Janssen Pharmaceuticals to Boston University that funds a study of the pathogenesis of chronic obstructive pulmonary disease. V. J. Carey has received research support from Bayer , Inc. H. Mirzakhani has received research support from the NHLBI . The rest of the authors declare that they have no relevant conflicts of interest.
Funding Information:
The National Health, Lung and Blood Institute (NHLBI) awarded Grants R01 HL091528 and UH3 OD023268 to S. T. Weiss and A. A. Litonjua. Y-C. S. Chen is supported by Grants T-32 HL007427 and T-32 AI007306 from the NHLBI. K. A. Lee-Sarwar is supported by Grant K08 from the NHLBI (K08HL148178), and H. Mirzakhani is supported by Grant K01 from the NHLBI (1K01HL146977-01A1).Conflicts of interest: A. A. Litonjua has received author royalties from UpToDate, Inc. S. T. Weiss has received royalties from UpToDate, Inc. L. B. Bacharier participates on the Data Safety Monitoring Board of DBV Technologies. A. Beigelman has received research support from the NHLBI and holds stock from DBV Technologies. R. S. Zeiger is a consultant for AstraZeneca, DBV Technologies, Genentech, Inc, GlaxoSmithKline, Novartis, and Regeneron, and has received research support from Aerocrine, AstraZeneca, Genentech, Inc, GlaxoSmithKline, MedImmune, Merck, the NHLBI, Quest Diagnostics, and TEVA Pharmaceuticals. G. T. O'Connor is a coinvestigator on a grant from Janssen Pharmaceuticals to Boston University that funds a study of the pathogenesis of chronic obstructive pulmonary disease. V. J. Carey has received research support from Bayer, Inc. H. Mirzakhani has received research support from the NHLBI. The rest of the authors declare that they have no relevant conflicts of interest.
Publisher Copyright:
© 2021 American Academy of Allergy, Asthma & Immunology
PY - 2021/10
Y1 - 2021/10
N2 - Background: The role of prenatal vitamin D sufficiency and supplementation in the development of childhood aeroallergen sensitization and allergic rhinitis remains uncertain. Objective: To describe the association of prenatal vitamin D sufficiency with childhood allergic outcomes in participants of the Vitamin D Antenatal Asthma Reduction Trial, a randomized controlled trial of prenatal vitamin D supplementation. Methods: We included 414 mother–offspring pairs with offspring aeroallergen sensitization data available at age 6 years in this analysis. We examined the association between prenatal vitamin D sufficiency status, based on vitamin D levels measured in the first and third trimesters, or vitamin D supplementation treatment assignment with the outcomes of aeroallergen sensitization, parent-reported clinical allergic rhinitis, parent-reported clinical allergic rhinitis with aeroallergen sensitization, food sensitization, any sensitization, eczema, and total IgE at ages 3 and 6 years. Results: Compared with early and late insufficiency, early prenatal vitamin D insufficiency with late sufficiency was associated with reduced development of clinical allergic rhinitis with aeroallergen sensitization at 3 years (adjusted odds ratio [aOR] = 0.34; 95% confidence interval [CI], 0.13-0.82; P =.02) and 6 years (aOR = 0.54; 95% CI, 0.29-0.98; P =.05). At 6 years, clinical allergic rhinitis with sensitization was significantly decreased in offspring whose mothers received high-dose vitamin D (aOR = 0.54; 95% CI, 0.32-0.91; P =.02) compared with offspring whose mothers who received low-dose vitamin D. Associations of prenatal vitamin D with aeroallergen sensitization were strengthened among children who also developed asthma or who had a maternal history of atopy. Conclusions: Among mothers with first-trimester vitamin D insufficiency, we detected a protective effect of third-trimester prenatal vitamin D sufficiency on the development of clinical allergic rhinitis with aeroallergen sensitization at ages 3 and 6 years.
AB - Background: The role of prenatal vitamin D sufficiency and supplementation in the development of childhood aeroallergen sensitization and allergic rhinitis remains uncertain. Objective: To describe the association of prenatal vitamin D sufficiency with childhood allergic outcomes in participants of the Vitamin D Antenatal Asthma Reduction Trial, a randomized controlled trial of prenatal vitamin D supplementation. Methods: We included 414 mother–offspring pairs with offspring aeroallergen sensitization data available at age 6 years in this analysis. We examined the association between prenatal vitamin D sufficiency status, based on vitamin D levels measured in the first and third trimesters, or vitamin D supplementation treatment assignment with the outcomes of aeroallergen sensitization, parent-reported clinical allergic rhinitis, parent-reported clinical allergic rhinitis with aeroallergen sensitization, food sensitization, any sensitization, eczema, and total IgE at ages 3 and 6 years. Results: Compared with early and late insufficiency, early prenatal vitamin D insufficiency with late sufficiency was associated with reduced development of clinical allergic rhinitis with aeroallergen sensitization at 3 years (adjusted odds ratio [aOR] = 0.34; 95% confidence interval [CI], 0.13-0.82; P =.02) and 6 years (aOR = 0.54; 95% CI, 0.29-0.98; P =.05). At 6 years, clinical allergic rhinitis with sensitization was significantly decreased in offspring whose mothers received high-dose vitamin D (aOR = 0.54; 95% CI, 0.32-0.91; P =.02) compared with offspring whose mothers who received low-dose vitamin D. Associations of prenatal vitamin D with aeroallergen sensitization were strengthened among children who also developed asthma or who had a maternal history of atopy. Conclusions: Among mothers with first-trimester vitamin D insufficiency, we detected a protective effect of third-trimester prenatal vitamin D sufficiency on the development of clinical allergic rhinitis with aeroallergen sensitization at ages 3 and 6 years.
KW - Aeroallergen sensitization
KW - Allergic rhinitis
KW - Prenatal
KW - Vitamin D
UR - http://www.scopus.com/inward/record.url?scp=85117007473&partnerID=8YFLogxK
U2 - 10.1016/j.jaip.2021.06.009
DO - 10.1016/j.jaip.2021.06.009
M3 - Article
C2 - 34166843
AN - SCOPUS:85117007473
VL - 9
SP - 3788-3796.e3
JO - Journal of Allergy and Clinical Immunology: In Practice
JF - Journal of Allergy and Clinical Immunology: In Practice
SN - 2213-2198
IS - 10
ER -